EMvision Medical Devices (ASX:EMV) Research & Development: A$3.94 Mil (TTM As of Dec. 2025)


ASX:EMV EMvision Medical Devices Ltd ASX:EMV
33 GF Score
Price A$1.52
! 3 Warning Signs
View Full Analysis

What is EMvision Medical Devices Research & Development?

EMvision Medical Devices ASX:EMV +2.36% 33 Research & Development is A$3.94 Mil as of Dec. 2025. GuruFocus rates ASX:EMV with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. EMvision Medical Devices's Research & Development for the six months ended in Dec. 2025 was A$1.72 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.94 Mil.

EMvision Medical Devices  (ASX:EMV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

EMvision Medical Devices Research & Development Related Terms

EMvision Medical Devices Research & Development Historical Data

* Premium members only.

The historical data trend for EMvision Medical Devices's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EMvision Medical Devices Research & Development Chart

EMvision Medical Devices Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 2.71 2.33 2.01 4.70 4.04

EMvision Medical Devices Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 2.84 1.82 2.22 1.72
ASX:EMV
33GF Score
EMvision Medical Devices Ltd ASX:EMV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EMvision Medical Devices Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$3.94 Mil mean?
EMvision Medical Devices (ASX:EMV) has a Research & Development of A$3.94 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on EMvision Medical Devices and its competitors.
Is EMvision Medical Devices' Research & Development too high?
EMvision Medical Devices' current Research & Development is A$3.94 Mil. Overall, EMvision Medical Devices has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does EMvision Medical Devices' Research & Development compare to ABT and SYK?
EMvision Medical Devices' Research & Development of A$3.94 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on EMvision Medical Devices and its competitors. EMvision Medical Devices's current Research & Development is A$3.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EMvision Medical Devices stock overvalued right now?
EMvision Medical Devices (ASX:EMV) has a current Research & Development of A$3.94 Mil. The current Research & Development is A$3.94 Mil. EMvision Medical Devices' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For EMvision Medical Devices (ASX:EMV), the current Research & Development is A$3.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EMvision Medical Devices Business Description

Address 65 Epping Road, Suite 4.01, Macquarie Park, Sydney, NSW, AUS, 2113
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
33GF Score

Get the complete analysis for ASX:EMV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.52
Price